Gilead Buying Another Cancer-Drug Partner -- Market Talk
Dow Jones04-07
1023 ET - Gilead Sciences is buying out another cancer-drug partner with its deal to pay up to $5 billion for Tubulis. Gilead in February said it would buy the rest of Arcellx, its partner in developing a potential CAR T-cell therapy for the blood cancer multiple myeloma, in a deal valuing the biotech company at about $7.8 billion at closing. Analysts at RBC Capital Markets say the Tubulis acquisition represents a strategically sound bolt-on that addresses Gilead's oncology pipeline growth needs while securing differentiated next-generation antibody-drug conjugate platform capabilities. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
April 07, 2026 10:23 ET (14:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments